FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to oncology, and can be used to predict the outcome of advanced ovarian cancer following adjuvant chemotherapy according to the AP regimen (cisplatin 75 mg/m2 + doxorubicin 50 mg/m2). That is ensured by single-stage detection of levels of viral endothelial growth factor (VEGF-A) matrix RNA (mRNA) and cross-complementing excision repair complementary (ERCC1) genes. Determination of the levels of the matrix RNA is carried out in the tumor tissue of the primary patient, obtained intraoperatively, with subsequent calculation of the integral index I according to the proposed formula, and if I<2, the prediction is considered positive with probability of 81 %, and if I>2, the prediction is considered to be unfavorable in 75 % of the cases.
EFFECT: invention provides prediction of the ovarian cancer outcome following the adjuvant chemotherapy according to the AP regimen for individualizing the approach and improving the clinical outcomes of the patients.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING DURATION OF DISEASE-FREE INTERVAL AFTER COMPLETION OF PRIMARY TREATMENT OF PATIENTS WITH OVARY CANCER | 2018 |
|
RU2676702C2 |
| METHOD FOR PREDICTING RECURRENCE OF SEROUS OVARIAN CARCINOMA | 2020 |
|
RU2749361C1 |
| METHOD FOR DIAGNOSING BREAST CANCER AND OVARIAN CANCER BY MMP-9 MRNA LEVEL IN BLOOD PLASMA | 2020 |
|
RU2745424C1 |
| METHOD FOR PREDICTION OF CYTOREDUCTIVE SURGERY VOLUME IN PATIENTS WITH ADVANCED OVARIAN CANCER AFTER COMPLETION OF THIRD COURSE OF NEOADJUVANT CHEMOTHERAPY | 2017 |
|
RU2671409C2 |
| METHOD FOR ASSESSING PRIMARY RESPONSE TO COMBINED CHEMOTHERAPY OF SPORADIC OVARIAN CANCER OF STAGES III AND IV | 2021 |
|
RU2769543C2 |
| TEST-SYSTEM FOR PREDICTION OF RELAPSE DEVELOPMENT IN PATIENTS WITH UTERINE CORPUS CANCER BASED ON EXPRESSION LEVEL OF THE ESR1 GENE | 2017 |
|
RU2661599C1 |
| METHOD FOR PREDICTING THE OUTCOME OF A DISEASE IN PATIENTS WITH LUMINAL AND THRICE NEGATIVE BREAST CANCER IN PATIENTS WHO DID NOT RECEIVE CHEMOTHERAPY OR HORMONE THERAPY IN THE NEOADJUVANT REGIMEN | 2017 |
|
RU2648523C1 |
| METHOD FOR PREDICTING THE PROGRESSION OF CERVICAL CANCER IN PATIENTS WITH STAGE IIB | 2022 |
|
RU2789500C1 |
| METHOD OF COMBINATION TREATMENT OF NON-SMALL CELL LUNG CANCER STAGE 1B-111 WITH CUSTOMIZATION OF ADJUVANT CHEMOTHERAPY | 2015 |
|
RU2593342C1 |
| METHOD FOR PREDICTING NON-METASTATIC SURVIVAL IN PATIENTS WITH BREAST CANCER ON THE BASIS OF EXPRESSION OF SOMATIC-STEM TRANSITION GENES IN RESIDUAL TUMOR AFTER PRE-OPERATIVE TREATMENT | 2018 |
|
RU2682879C1 |
